NasdaqGS - Delayed Quote USD

Myriad Genetics, Inc. (MYGN)

18.49 -0.01 (-0.05%)
At close: April 22 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Paul J. Diaz CEO, President & Director 2.31M -- 1962
Dr. Kevin Richard Haas Ph.D. Chief Technology Officer 580.36k -- 1986
Mr. Mark S. Verratti Chief Commercial Officer 915.81k -- 1968
Mr. Scott J. Leffler Chief Financial Officer -- -- 1975
Mr. Samraat S. Raha Chief Operating Officer 514.76k -- 1973
Ms. Natalie Munk Principal Accounting Officer -- -- 1981
Dr. Dale Muzzey Ph.D. Chief Scientific Officer 816.5k -- 1980
Mr. Matthew Scalo Senior Vice President of Investor Relations -- -- --
Mr. Glenn Farrell Senior VP & Chief Marketing Officer -- -- --
Ms. Shereen Solaiman Chief People Officer -- -- 1973

Myriad Genetics, Inc.

322 North 2200 West
Salt Lake City, UT 84116
United States
801 584 3600 https://www.myriad.com
Sector: 
Healthcare
Full Time Employees: 
2,700

Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Myriad Genetics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 5; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 01, 2024 - May 06, 2024
Myriad Genetics, Inc. Earnings Call

Related Tickers

VCYT Veracyte, Inc.
19.85
+2.06%
 
NEO NeoGenomics, Inc.
13.42
-0.81%
 
CDNA CareDx, Inc
8.17
-1.68%
 
OLK Olink Holding AB (publ)
22.03
+0.73%
 
RVTY Revvity, Inc.
100.77
-0.09%
 
NTRA Natera, Inc.
88.61
+3.90%
 
RDNT RadNet, Inc.
47.65
+2.43%
 
DGX Quest Diagnostics Incorporated
130.09
+1.28%
 
BNR Burning Rock Biotech Limited
0.8600
+19.44%
 
LAB Standard BioTools Inc.
2.5400
+0.79%